Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
June 14, 2021 17:08 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and...
Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients
June 14, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.)...
Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop...
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
May 19, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for...
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
May 17, 2021 07:15 ET
|
Landos Biopharma, Inc.
Completed initial public offering of common stock, raising approximately $100 million in gross proceeds Following positive Phase 2 results of omilancor in ulcerative colitis, including...
Landos Biopharma与联拓生物宣布独家合作和许可协议，将携手在中国和亚洲特定市场对新药Omilancor和NX-13进行开发和商业化
May 17, 2021 07:00 ET
|
Landos Biopharma, Inc.
布莱克斯堡（美国弗吉尼亚州）、上海（中国）和普林斯顿（美国新泽西州）, May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma,...
Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets
May 17, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., and SHANGHAI, China and PRINCETON, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery...
Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease
May 06, 2021 16:01 ET
|
Landos Biopharma, Inc.
Company’s second omilancor program entering a Phase 2 study with plans to pursue at least five autoimmune indications Topline results are expected in the second quarter of 2022 BLACKSBURG, Va., May ...
Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis
April 29, 2021 07:00 ET
|
Landos Biopharma, Inc.
Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 ...
Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting
April 26, 2021 07:00 ET
|
Landos Biopharma, Inc.
Robust preclinical data supports breadth and growth of Landos’ autoimmune-focused pipelineCompany expects to submit an IND for omilancor as a topical treatment for psoriasis in 2H 2021Company expects...